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What happens after James Lind Alliance
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Abstract
Background: The James Lind Alliance (JLA) supports priority setting partnerships (PSPs) in which patients, carers
and health professionals collaborate to identify a Top 10 list of research priorities. Few studies have examined how
partnerships plan for the post-prioritisation phase, or how context and post-PSP processes influence the fortunes of
priorities. This evaluation aimed to explore these questions.
Methods: We selected a diverse sample of 20 interviewees who had knowledge of 25 PSPs. Thirteen interviewees
had led a PSP, either from a university, patient organisation or charity. Three were patients who had taken part in a
PSP workshop. Four others, three researchers and one funder, had worked with JLA PSP priorities to develop
research proposals. We analysed the data thematically, exploring how success was understood and achieved.
Results: The JLA PSPs had different histories, funding sources, goals and stakeholders. Whilst their focus was on
generating priority research topics, PSPs’ wider impacts included enhanced status and greater confidence for
individuals, as well as relationship-building and network strengthening for the organisations involved. To follow
through on a Top 10, additional work was needed to refine broad priority topics into research questions and match
them with appropriate funding sources. Commitment to post-PSP action from partners appeared to increase the
chance that priority topics would be followed through to funded studies. Academic publications could alert
researchers to a PSP’s outputs, but not all PSPs had the capacity to produce them. A Top 10 list potentially
influences funding decisions through direct funding, themed calls or as a prompt in open calls. Influence on
funders appears to depend on alignment between a priority and the funder’s remit, culture and values.
Conclusion: The history and context of a JLA PSP have a major influence on its impact. Our findings suggest that
there is no universal formula for success, but that greater resource and attention should be given to what happens
after prioritisation. Further research is needed on what works best in what circumstances. Overall, we conclude that
a wider cultural change in the research world is needed for JLA PSPs to achieve their goal of shaping the research
agenda.
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Plain English summary
The James Lind Alliance (JLA) supports priority setting
partnerships (PSPs) where patients, carers and health
professionals work together to decide research priorities.
Few studies have examined the impact of these priorities
on research, or how impact was achieved. We explored
impact through interviews with 20 people, who had been
involved in a JLA PSP, or had worked with the Top 10
priorities. An Advisory Group helped to select the inter-
viewees and questions asked. The project team looked at
the interview transcripts for common themes and any
differences.
JLA PSPs have unique histories, goals and people in-
volved which affect the nature of their success. While
they often lead to newly funded research, PSPs’ wider
impacts include enhanced status and confidence for in-
dividuals, as well as relationship-building and network
strengthening for the organisations involved. Additional
work is needed post-PSP to change broad priorities into
research questions. Journal articles alert researchers to
the priorities, but not all PSPs can produce them. Re-
search funders can respond to a priority through direct
funding or calls for proposals. Influence on research fun-
ders appears to depend on a match between a priority
and the funder’s remit, culture and values.
There is no universal formula for success, but greater
resource and attention should be given to what happens
after the Top 10. Further research is needed on what
works best in what circumstances. Overall, we conclude
that a deeper cultural change in the research world is
needed for JLA PSPs to achieve their goal of shaping the
research agenda.
Background
The James Lind Alliance (JLA) supports priority setting
partnerships (PSPs) in which patients, carers and health
professionals collaborate to identify priority topics for
new research, usually generating and publishing a Top
10 list [1]. Few studies have examined how partnerships
plan for the post-prioritisation phase, or how context
and post-PSP processes influence the fortunes of priority
lists. We aimed to explore these questions through an
evaluation of a range of JLA PSPs.
The JLA was established in 2003 with the goal of in-
volving patients, carers and health professionals in shap-
ing the research agenda [2, 3]. Its founders’ vision was
that JLA partnerships would work together to review
existing evidence on the treatment of a particular condi-
tion and identify and prioritise knowledge gaps. The
scope of JLA PSPs now includes cause, diagnosis, social
care and prognosis [4], and topics other than health con-
ditions. It has become a popular and widely-used ap-
proach to research priority setting.
In 2013 the JLA became a partner organisation of the
National Institute for Health Research (NIHR). The JLA
Secretariat, made up of 2.5 full-time equivalent staff, is
based at the Wessex Institute in Southampton, UK. It is
responsible for maintaining the infrastructure and web-
site, as well as contracting a network of ‘JLA Advisers’
who support the PSPs. The JLA Guidebook (now in its
8th edition) [5] details the structured JLA approach.
PSPs can be initiated and led by anyone with a connec-
tion to the PSP’s topic (including a healthcare profes-
sional, patient, carer or researcher). Each PSP has a
steering group which coordinates and implements the
activity of the PSP. It includes patients, carers and clini-
cians and a JLA Adviser. Funding for PSP activity can be
provided by organisations, charities and/or PSP partners
with no commercial interest in the topic.
The recommended PSP process has developed over
time. It now consists of eight steps after funding has
been secured: form a steering group to lead the prior-
ity setting partnership; gather research uncertainties
via a survey; categorise the survey responses to gener-
ate a longlist of uncertainties (40–70); prioritise this
list in a second survey checking none have already
been researched thus generating a short list (20–30);
hold a final priority setting workshop to generate a
Top 10 from the short list; publish both the short list
and the Top 10; work with funders and researchers
to influence their decisions; and monitor and evaluate
the impact of the priorities [5–7]. The first six steps
are well-established and highly structured. The last
two have been added recently and are less well-
developed. Whilst feedback from PSPs does filter into
the JLA Guidebook as part of a regular review, there
is no formal process for sharing learning between
PSPs, especially on how to maximise impact from the
Top 10 list.
The first JLA PSP on asthma was published in 2010 [8].
The approach has since been used by over 100 priority
setting partnerships [4], mostly in the UK [9], but also in
Canada [10, 11], Europe [12] and Africa [4]. The published
literature on JLA PSPs is largely descriptive of the pro-
cesses used by PSPs and their priorities [9]. To our know-
ledge, there has not been a formal audit of how many JLA
Top 10 topics have received research funding, nor an in-
depth evaluation of the impact of PSPs. This study aimed
to highlight and begin to fill that gap.
Our research question had several parts. We first
asked people who had participated in a JLA PSP or
responded to a JLA PSP priority, what impacts they
had identified. We then asked how these impacts had
been influenced by the context and by processes after
the PSP. We were interested in exploring not only
the impacts on the commissioning or funding of new
research, but also the impacts on the people and the
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partner organisations. We hoped the findings would
be useful to past, present and future PSPs.
Methods
Management and governance
The study formed part of the Partnerships for Health,
Wealth and Innovation theme in the NIHR Oxford Bio-
medical Research Centre (BRC) [13] and was conducted
by two independent researchers, SC and KS. It was over-
seen by an Advisory Group of 11 people bringing the
perspectives of patients, carers, PSP Leads from a charity
or university context, health researchers, funders of re-
search, experts in public involvement in research and a
JLA Adviser. The Advisory Group helped to shape the
project plans, agreeing the criteria used to choose inter-
viewees (see Supplementary Material), and the broad
topics explored in the interviews. They also reviewed the
findings to help develop recommendations. The JLA
Secretariat had no role in the project, other than identi-
fying and accessing some interviewees.
The three patients/ carers on the Advisory Group were
paid for their time and expenses. They were invited to
join the Group because they had extensive experience of
being involved in PSPs and/or were patient leaders in
the field of public involvement in research. Along with
all Advisory Group members, they were known to be re-
flective and constructively critical of their experiences of
the JLA approach.
Study design
Our approach was based on illuminative evaluation,
which uses qualitative methods to explore the rationale,
development, operations, achievements, and difficulties
of an initiative [14]. It relies on engaging a wide range of
stakeholders and capturing their perspective on what
counts as impact, rather than judging the initiative
against fixed external criteria.
Sampling
We sought a diverse sample of interviewees who had
organised or contributed to PSPs in a variety of roles
and contexts (patients, carers and clinicians), or had
worked with JLA PSP priorities to develop research pro-
jects or funding calls (researchers, staff from funding or-
ganisations). The final candidates were chosen to
maximise the range of perspectives on the key questions
identified with the Advisory Group. They fell into the
categories listed in Table 1. A selection matrix made the
questions and the criteria for selection transparent (see
Supplementary Material). PSP interviewees were re-
cruited with advice from the JLA secretariat and two
JLA advisers. Open recruitment of researchers was via
an advert on social media. Others were recruited via
snowball sampling, through interviews with PSP Leads.
Interviews
Interviewees were invited by email and gave informed
consent to take part. Telephone interviews were con-
ducted in April–May 2019 and lasted 30–60 min. Semi-
structured interview schedules were individualised to re-
flect the expertise and experience of each interviewee,
but all interviews covered the following topics, where
relevant:
– Who led the PSP – and who owns the outputs?
– What was the dissemination strategy?
– How have funders worked with the priority lists
generated by this PSP?
– How have researchers worked with the priority lists?
– How has being involved in the PSP affected partner
organisations?
– How has being involved in the PSP affected
individuals?
– Examples of indirect impacts?
The interviews took the form of an exploratory con-
versation which allowed the interviewee to identify and
explore topics important to them. All interviews were
digitally recorded and transcribed. Recordings and
pseudo-anonymised transcripts were stored on the Ox-
ford University secure IT network. Whilst most inter-
viewees were comfortable to be identified, one or two
wished to be fully anonymised. Therefore some quotes
have not been attributed to a particular PSP.
Data analysis and synthesis
The researchers read all transcripts and agreed the broad
themes, partly informed by discussions with the Advis-
ory Group. Their analysis took the form of inductive
thematic analysis [15], so that the themes were gener-
ated from the data up, identifying common themes –
topics, ideas and patterns of meaning that came up re-
peatedly – and noting differences. Their interpretation
was influenced by their standpoints as people working
outside academia, with extensive experience of develop-
ing or supporting JLA PSPs, and of patient and public
involvement in research. The findings have been pub-
lished separately [16] and developed further for this art-
icle in discussion with TG, MM and JC.
Results
We have categorised our findings in relation to the con-
textual and process factors that influenced outcomes
and impacts. These are discussed in turn.
Contextual factors influencing PSP impact
The JLA PSPs in our sample had been established by dif-
ferent groups for different reasons, and this was an im-
portant factor explaining their outputs and impacts. The
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PSP’s goals were influenced by the mission, capacity,
practical constraints and influence of the lead organisa-
tion, a charity, patient organisation or academic institu-
tion. Some PSPs had set out to raise the profile of an
underfunded research area. Others had aimed to
broaden the scope or rank competing priorities in an
area that was already popular or where priorities were
contested. What counted as success therefore depended
on the PSP’s starting point.
The wider political context to a PSP also influenced its
process and outcomes. For example, in the chronic Lyme
Disease PSP (a clinical condition whose origin and treat-
ment is contested), the patient organisation was unable to
recruit any clinical researchers for the Steering Group.
The PSP Lead from Lyme Disease Action, reported that
that some clinical researchers seemed to feel that the PSP
“shouldn’t even be happening”. Seven years later, the Lyme
Disease PSP priorities have yet to be addressed by any re-
search in the UK, although some interest has been shown
by other countries. Simply running a PSP cannot re-
solve historical or existing tensions in a research
community, though it may help to move some de-
bates forward.
Post-PSP processes influencing impact
We have summarised these findings under seven broad
themes related to post-PSP activity: planning for the end
of the PSP, disseminating the Top 10, persuading fun-
ders and researchers to respond to the priorities, using
JLA PSP research priorities to influence strategy and
funding decisions, translating priority topics into re-
search questions, evaluating the impact of a PSP, and
the post-PSP impacts on people and organisations.
Planning for the end of the PSP
Following the recommendations in the current JLA
guidebook [5], most PSP Leads in our sample had devel-
oped a comprehensive communications plan to raise
awareness of their Top 10 research priorities and often
the shortlist- considered at their final workshop. How-
ever, many PSP Leads questioned whether simply
informing others of the outputs was sufficient to have
impact. On reflection, they concluded they needed a
more strategic approach to their post-PSP activity:
“ … there's no point in identifying your Top 10, if
you don’t have a plan of what you're going to do
with them afterwards. We underestimated the work
that’s required if you want to really make the best
use of the results.” - PSP Lead, Charity, Funder
Some reported having overlooked issues that could
have been addressed in early planning, such as: consider-
ing how to achieve each of the PSP’s strategic goals;
agreeing who will ‘own’ the PSP priority list; considering
how the PSP will respond to non-research questions (for
example, statements about deficiencies in current ser-
vices); and capitalising on the skills, experience and net-
works that had been developed through the partnership.
Others described having made such plans. For ex-
ample, the charity-led Mental Health in Children and
Young People PSP (2018) aimed to raise professional
and public awareness of mental health issues in young
people as an additional outcome. They therefore in-
cluded an All Party Parliamentary Group event in Parlia-
ment in their dissemination plan. The Type 2 Diabetes
PSP (2017), led by Diabetes UK, built alliances within
their organisation to facilitate dissemination of priorities
Table 1 Different categories of interviewee (the total adds up to more than 20 because some interviewees fell into more than one
category)





A person who led the work of a PSP as a key member of the Steering Group, and was





A person who led the work of a PSP, as a key member of the Steering Group, and was




A person who led the work of a PSP, as a key member of the Steering Group, and was




A person who led the work of a PSP, as a key member of the Steering Group, and was
employed by a clinical organisation such as a hospital trust.
1
Public Funder A manager from an organisation that allocates public funds to health research. 1
Clinician A clinician who took part in a PSP and reflected on the impact on their practice. 2
Patient A patient who took part in a PSP and reflected on the impact on their life and work. 3
Researcher A researcher that did not take part in a PSP, but worked with a Top 10 priority list. 3
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(via the communications department) and address topics
relating to service improvement outside the remit of the
PSP (via the quality department). They also engaged ex-
ternal partners at the beginning with a view to develop-
ing joint funding calls at the end.
Disseminating the top 10 priority list
Typically, all or most partner organisations involved in a
PSP helped with dissemination of the outputs. Large or-
ganisations leading PSPs usually had communications
teams to provide expert advice and resource for this.
Target audiences included patients, carers and the pub-
lic, research funders, policy makers, health professionals,
lay media and researchers. Interviewees felt that it was
important to convey details of how Top 10 lists are gen-
erated. They considered that few other researchers, jour-
nal editors or academic reviewers fully understood or
valued the rigour of the process:
“I don’t think they realise that the process has been
quite long, very involved, and involved hundreds of
people in different ways.” - Researcher
Successful dissemination strategies included: a press
release summary of the Top 10 embargoed until launch
day; a launch event e.g. at a scientific conference; a plain
English summary for patients and carers; an academic
journal article; social media activity e.g. releasing one
priority per day over 10 days, or a guest blog; hosting a
web page; using email lists of PSP survey participants;
giving talks to patient, clinical and scientific groups; a
funding organisation alerting current and past grant
holders; using the channels and networks of partner or-
ganisations e.g. their newsletters; and promoting findings
by word of mouth.
Many PSPs involved patients, carers and clinicians in
their dissemination activity, based on the rationale that
this gave the messages greater credibility and authenticity.
Some PSPs in our sample had successfully published
their findings in academic journals, hoping to reach re-
searchers in the field. However, some had experience of
having papers rejected, because the identified priorities
were not considered to be ‘new knowledge’. Some inter-
viewees suspected this was because the JLA approach
was no longer seen as novel. In some cases, the PSP
team lacked the expertise to write academic articles and
navigate the publication process. They saw this as a
missed opportunity.
“ … all we could do was link to the article on our
website … a clinician, if they see that the link is to a
patient website, they’re not going to take it so ser-
iously, but if we had had an [academic] paper, that
would have been an anchor, more trustworthy from
their point of view.” - PSP Lead, Charity, Non-
funder
One interviewee expressed uncertainty about the sta-
tus of priority setting as a topic for academic publica-
tion, especially in relation to the narrow formats deemed
appropriate for many clinical journals:
“I don’t think any journal’s going to be interested in
our Top 10 … It doesn’t seem scientific, there’s no hy-
pothesis. There isn’t really a research question … it's
more social science isn't it?” - PSP Lead, Academic
Institution
PSP Leads reported varied experience in achieving na-
tional news coverage. Several had been told that their
priority list was not “newsworthy”. They felt that science
journalists were more interested in reporting scientific
‘breakthroughs’ rather than how the research question
came about. The PSPs that had received mainstream
media coverage had made links with reporters with per-
sonal or family experience of the condition.
Some interviewees concluded that the main audience
for Top 10s was researchers and more effort was needed
to reach them. While some had produced a lengthy re-
port for their patient/carer community, they were doubt-
ful of its value and concluded that a short report would
be sufficient.
“It’s this thing about charities constantly churning
out PDF reports and you need to make sure you’re
asking yourself ‘What is the point, right? Like who is
reading this?’” PSP Lead, Charity, Funder
Persuading others to respond to the top 10
The key stakeholders that PSPs aimed to influence were
funders, researchers and donors. In order to get their
priorities addressed by external funders, PSP partners
first needed to identify whom to influence and then tar-
get activities towards these individuals or organisations.
However, this sometimes proved challenging – for ex-
ample, if the funding body did not recognise the JLA
process or value its outputs.
Interviewees from external funding bodies emphasised
that JLA priority lists were only one of many influences
on their portfolio, which typically took account of the
organisation’s remit and mission, its accountabilities to a
wide range of stakeholders, prevailing scientific and pol-
icy priorities, and the opinions of review panels – as well
as the amount of funding available: “Sometimes it’s a
question of who is the best funder of this research … and
often that’s not us.” – Funder.
Involving external funders directly by inviting them to
Steering Group meetings or workshops, or involving them
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indirectly (e.g. by using their premises for meetings) was
not found to be sufficient by PSP Leads to influence those
funders’ decisions. At best, it helped to start a relationship.
Greater value seemed to come from PSP partners working
closely with funders in the post-PSP phase – for example
to develop themed calls (see below).
PSP Leads emphasised the value of using influencing
skills at this stage, which might require involving differ-
ent people from the team that ran the PSP. Whilst
ideally a PSP would include individuals with all the rele-
vant skills, several PSPs in our sample either had not
planned for this, or lacked resources. PSP Steering
Groups sometimes felt exhausted by the time they “got
their PSP over the finishing line” (Advisory Group Mem-
ber), and because funding had ended, key individuals
had little time or energy for follow-up.
Loss of momentum at the post-PSP stage was a par-
ticular problem for PSPs which lacked a strong sponsor
such as patient organisation or charity. Cellulitis, for ex-
ample, is a potential complication of numerous other
conditions. No organisation existed for cellulitis itself.
As the PSP Lead explained, this meant that the Cellulitis
PSP, “… didn’t have a critical mass of people willing to
keep it up in the air.” This was in contrast to the same
interviewee’s experience of leading the Eczema PSP
which had the strength of the Eczema Society behind it.
In terms of influencing researchers, our interviews
suggested that researchers tended to use a Top 10
priority to strengthen the case for a study they
already planned to do. Some said the JLA PSP gave
them confidence and motivation to persist with apply-
ing for a grant on a prioritised topic. We heard no
reports of researchers changing their research plans
to pick up a PSP priority, nor of researchers stopping
pursuing an area of interest because it was not on a
priority list.
"It [the Top 10] was great for including in these sec-
tions of the grant and fellowship applications about
what is the impact of your research going to be, and
what’s the need for this research. - Researcher
Where an academic institution had led a PSP, the part-
nership was keen to emphasise that that the Top 10 list
was not ‘owned’ by them, but meant for all researchers in
their field. In one such example, working in partnership
with a charity was found to be an effective means of
reaching and potentially influencing others. In this case,
the charity’s CEO provided the missing skills and links
with the wider research community, as well as acting as
an ‘honest broker’ from "an organisation that doesn’t have
any skin in the game" [PSP Lead, Charity, Funder].
Finally, in relation to donations, some of the patient
interviewees felt that a Top 10 could provide an effective
focus for fundraising by patients and carers. Some
charity-led PSPs reported that the JLA process had in-
deed helped to convince their donors that specific re-
search projects were worthy of their support:
If you can show with clarity that you’re representing
the priorities of your people … that is enormously
powerful and it gives you enormous confidence in
terms of going out there and speaking about what
you do, especially with donors … -PSP Lead, Charity,
Funder
Using the priorities to influence funder strategy and
decisions
When a PSP was led by an organisation that funds re-
search, there were several ways in which priorities were
used to influence its own funding decisions and those of
other funders: integrating these into organisational re-
search strategy; directly funding research studies; sharing
the list with other related funders and seeking their in-
put to joint programmes of research; putting out themed
calls for research proposals; integrating priority topics
into open calls for funding applications; or using the pri-
orities as a criterion when judging the importance of re-
search proposals:
“[The JLA PSP has] given us justification to prioritise
and rationalise with the research community, be-
cause people with [this condition] have told us what
they want us to do. What was also important was
making sure our Board of Trustees knew about those
ten priorities, because now we've got a Board that
understands and wants us to report against them.” -
PSP Lead, Charity, Funder
Some funders had successfully worked together to de-
velop research calls on shared priorities e.g. Parkinson’s
UK joined forces with Marie Curie and other charity
PSPs where a question about managing incontinence
featured in their Top 10. Several of the PSP Leads inter-
viewed from charities, were also exploring the possibility
of their organisation putting out a joint call with the
NIHR.
Some Top 10-themed research calls generated a poor
response leading to the view that the research commu-
nity lacked the skills, capacity or willingness to address
the topic. Charity funders have taken additional steps to
bring researchers together to carry out foundational
work to develop new areas of research. For example, the
MS Society worked with research groups to develop a
plan for a clinical trial that was ultimately funded by a
charity in the USA. In another PSP, prevention and
minimising risk emerged as a priority topic, but capacity
in that area was limited, so the charity organised an
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international workshop to develop recommendations for
follow-up work.
Whilst one or two interviewees felt that all funded re-
search should reflect priority topics, others felt that pa-
tients, carers and clinicians involved in the process may
lack insight about potentially valuable research avenues:
“There will be some basic science questions that were
never going to be brought up in a PSP which could be key
to scientific and medical progress” – PSP Lead, Academic
Institution. None of the charities interviewed for this
study had made the decision to only fund JLA PSP prior-
ities. In open funding calls, JLA priority lists were one of
several criteria used by reviewers to assess applications.
Some interviewees raised concerns that researchers
might use a JLA PSP priority to ‘game the system’. For
example, by squeezing their preferred research idea into
a broad umbrella priority topic, or claiming that their
proposal addresses a JLA PSP without justifying this in
depth. Some charity funders assumed that the involve-
ment of patients and carers in the review process pro-
vided an adequate check. However, they were uncertain
how any grant reviewers assessed the researchers’ claims
in practice. Many interviewees also commented that ad-
dressing a Top 10 topic did not mean that researchers
could then ignore the patient voice in the subsequent re-
search process. On the contrary, as one PSP Lead de-
scribed, “the JLA is the beginning of an involvement
process [with patients]” - PSP Lead, Charity, Funder.
Translating a priority topic into a research project
Translating a Top 10 priority into a research project has
three steps: (1) mapping which aspects of the topic re-
main unanswered; (2) developing a focused research
question from the broad priority (where necessary); and
(3) designing a project to address the question. Many of
the PSPs in this sample had hosted workshops with re-
searchers to carry out this translation work. To our sur-
prise, few had involved patients and carers, though
several had involved clinicians. Yet our data suggested
that patient and carer involvement at this stage could re-
duce the risk of priorities being misinterpreted and
translated back into conventional clinician and re-
searcher framings.
“Question eight on our [Top 10] list is about how
parenting styles affect treatment outcomes for young
people with mental health problems. And it seemed
when we were talking to funders that they got the
wrong end of the stick about this … A lot of the re-
search that is out there is about how parents who
have a mental health problem affect their children.
That’s not what this question is getting at all … ”
PSP Lead, Mental Health in Children and Young
People
One PSP Lead described a situation in which a funder
had not worked with anyone from the PSP, and had de-
veloped a poor-quality call as a result:
“The funder did end up putting out a call on one of
the questions, but they didn’t speak to anyone before-
hand … and the call was so badly worded that no
one could put a research proposal together to answer
it. It just went unfunded.” - PSP Lead, Charity,
Funder
In another example, the NIHR put out a commission-
ing call in response to the priority topic ‘the manage-
ment of continence problems’ from the Childhood
Disability PSP. The call asked for a survey of current
NHS practice in this area. Parents of disabled children
who worked with researchers to respond to the call
pointed out that the proposed survey would fail to iden-
tify any measures taken by parents and families them-
selves. They included this omission in their successful
application, and two of the parents became co-
investigators on the funded study.
Evaluating the difference JLA PSPs are making to research
Interviewees from research charities reported assessing
the impact of their PSP by monitoring how many grant
applications addressed a priority topic. Some did this by
including a tick-box in their application form and sug-
gested that public funders such as NIHR follow suit.
Many PSP Leads had kept track of which priorities had
been addressed by funded research. For example, the
Mild to Moderate Hearing Loss PSP identified nine such
projects, including studentships, fellowships, systematic
reviews and a feasibility study. However, it is not helpful
to judge the impact of JLA PSPs simply in terms of how
much funding is allocated to their priorities, since some
research topics can be addressed with modestly-funded
studies, while others require an expensive clinical trial.
Some PSPs had been able to share details of research
progress with their patient, carer and researcher com-
munities. For example, the Tinnitus PSP (2012) pro-
duced a research update report for its members 5 years
later [17]. Two of the patient interviewees said they
found it hard to find the information they would like
about progress. It was unclear who had responsibility for
keeping such information up to date and whether it
should be held by the JLA Secretariat, PSPs, researchers
or funders.
Transforming: the impact of PSP involvement on individuals
and organisations
The experience of going through the JLA process was
reported to have a profound and mostly positive impact
on the people and organisations who took part. Patients
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and carers said they felt they had made a unique and
important contribution to their PSPs. They described
gains in knowledge and confidence which had affected
their own lives and work, and had led to an appetite
for subsequent involvement in research and cam-
paigning, although not all had been able to find such
opportunities:
“It was the first time that I realised that patients
should and could have a say in the whole healthcare
ecosystem. They weren’t just victims or the ‘done to’
but that they could positively impact what’s going
on.” - Patient participant in a PSP
Clinicians who had been involved in PSPs reported
that the experience had changed their clinical prac-
tice, making them more aware of patients’ concerns
and highlighting aspects of healthcare that need im-
proving. In some cases it enhanced their own visibil-
ity, status and credibility amongst peers. They also
felt more able and confident to involve patients and
carers in their work, and expanded their ‘involvement’
networks:
“The PSP brought me into contact with a patient
charity … I heard stories that I would never have
heard otherwise, about how doctors relate to pa-
tients, and how the words used are important such
as giving people fear, hope or being realistic.”
-Clinician lead, Inherited Anaemias PSP
Similar transformational changes were described by
organisations that had taken part in a PSP. The experi-
ence was reported to have enhanced their status and
credibility, for example, one charity described being seen
as “the” patient voice for their condition in the UK after
their PSP. Others reported a change in their organisa-
tions’ cultures and values towards more patient-centred
and collaborative ways of working. PSPs often left a
legacy of infrastructure, policies and projects to sup-
port ongoing patient involvement. Newly built or
strengthened networks encouraged partner organisa-
tions to continue working together on areas of com-
mon interest, and a shift to a more collaborative way
of working led to new approaches to working with
funded researchers.
Finally some PSPs reported success in transforming
national policy. The Tinnitus PSP identified an absence
of clinical guidelines for tinnitus in children and drew
on the PSP networks to convene an inter-professional
group to draft new guidance. The Canadian Dementia
PSP directly influenced the Canadian government’s de-
mentia strategy to highlight the issue of stigma and the
need for early treatment [18].
Discussion
Even within this small scale qualitative study of relatively
few PSPs we have begun to reveal a rich and complex
picture of what counts as outcomes and impacts of JLA
PSPs which goes far beyond simply funding research.
The context for each PSP is hugely significant. The start-
ing point of the PSP, what it aims to achieve, the individ-
uals involved, the organisations that lead it – all shape
the process and outcomes, making it difficult to draw
out general conclusions about ‘how to succeed’ and
broadening the definition of what success looks like.
Some PSPs, particularly in the early days, understood
the production of a Top 10 to be an end in itself, but
over time, a need to plan strategically and adequately re-
source an additional stage of post-PSP work has become
more apparent. The difficulty described by interviewees
in getting the outputs of JLA PSPs published in aca-
demic journals is concerning. Changes in the publishing
landscape in recent years such as the emergence of niche
journals like Research Involvement and Engagement and
the rise of open access publishing (requiring a publica-
tion fee) may also have influenced whether and where
JLA PSP findings appeared in the academic literature.
The evolving strength of the partnership itself and its
capacity to influence others seems as important as the
narrow product of a JLA PSP (the Top 10 list). Our find-
ings did not reveal a simple relationship between gener-
ating priorities and people acting on them. Rather,
priorities became transformed into funded projects when
patients, clinicians, researchers, funders and policy-
makers became aligned behind them, sometimes in in-
direct and non-linear ways. This reflects Carol Weiss’s
classic theoretical work in the sense that policy, in this
case research policy, is rarely directly knowledge-driven.
More often policy priorities emerge through a kind of
mutual enlightenment, in which different stakeholders,
through repeated interaction over time, come to under-
stand and value each other’s perspectives [19]. There are
different and sometimes competing understandings of
the concepts of research ‘use’ or ‘impact’. To communi-
cate more effectively in wider research policy making
and funding systems, PSPs need to understand how fun-
ders process evidence of priorities and the environments
in which they and researchers operate [20].
Lessons for improving the impact of priority setting
partnerships
Whilst it is impossible to provide a ‘blueprint’ for a suc-
cessful PSP, we offer some broad recommendations for
improving the process and maximising impacts in
Table 2. Since this project was completed, SC and KS
have discussed the findings with a wide range of stake-
holders in two separate workshops: The JLA Advisory
Group meeting and The Impact Coffee Club hosted by
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NIHR. The feedback was synthesised into a report for
the JLA community [21].
The recommendations from these workshops for the
JLA included [21]: creating new opportunities for shared
learning across PSPs, both past and present, in addition
to the current website advice; assessing a potential part-
nership’s readiness to address issues of impact as part of
the initial appraisal of PSPs; creating a library of JLA
PSP results; and, providing more information to PSPs
about the research funding landscape and how best to
work with funders. It was also suggested that research
funders and researchers improve their understanding of
how a Top 10 is generated and make better use of the
survey data that underpins each priority when develop-
ing new research questions. Funders could usefully share
their experience of assessing whether grant applications
genuinely address a JLA priority to develop best practice
guidance in this area.
Strengths and limitations of this study
To our knowledge, this is the first qualitative study of
how context and post-PSP processes influence outputs
and impacts. A systematic literature review was not con-
ducted to confirm this. The scope of the project was
limited by the modest budget and timescale. Our use of
exploratory, semi-structured interviews allowed partici-
pants to make sense of complex and emergent processes
and comment reflexively on what had occurred after
their PSP had finished. The lack of existing quantitative
data on impact collected across all PSPs or direct obser-
vation of actual PSP practices means that these retro-
spective accounts by interviewees could not be subject
to comparison or fully put into context. Despite these
limitations, however, we believe the study has begun to
scope the issue of JLA PSPs’ impact and usefully identi-
fied areas for future research and evaluation.
Conclusion
This illuminative evaluation of JLA PSPs has highlighted the
complex links between processes post-PSP. We have identi-
fied ways in which the JLA Secretariat and the PSPs them-
selves might maximise their influence. We have also shown
a vital need for parallel commitment from other parts of the
wider research system to adapt how they view and respond
to JLA PSP priorities. Whilst much progress has already been
made, much deeper and broader cultural change is required
to ensure that the goal of delivering research that is relevant
and useful to the end-users is truly achieved.
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Table 2 Suggestions for improving the impact of James Lind
Alliance Priority Setting Partnerships
For the JLA
➣ Extend JLA guidance to cover impact-oriented activity beyond pro-
ducing a Top 10 list
➣Ensure that JLA Advisors are trained and resourced to support
planning such activity
For JLA PSPs
At the planning stage:
➣ Consider who will own the Top 10 list once it has been produced,
and how the list might be taken forward
➣ Plan early for wide dissemination and associated networking and
lobbying activity
➣ Ensure that resources are allocated for such ‘post Top 10’ activities
During and after the Top 10 list has been produced:
➣ Make strategic use of patients, carers, clinicians and researchers in
promoting the Top 10 list
➣ Work with funders after dissemination of the Top 10 list, recognising
that (depending on culture, remit and priorities) they may not believe it
is their responsibility to address the priorities identified
➣ Work with clinicians, patients and carers to develop specific research
questions and projects from the Top 10 list
➣ Do foundational work to build researchers’ capacity and willingness
to respond (e.g. interdisciplinary workshops to promote collective
thinking)
For research funders, and researchers
➣ Recognise that patient, carer and clinician input has an important
place in research priority setting, and promote this culture in your
organisation
➣ Improve your understanding of the JLA process and its goals,
including how a Top 10 list is produced and what additional data may
be available from a JLA PSP
➣ Recognise that whilst some JLA PSP priority topics may not be new,
the way that patients, carers and clinicians frame their questions may
bring a different perspective, requiring a novel methodological response
and closer dialogue between researchers and patients, carers and
clinicians
➣ Recognise that not all research topics and questions should be
framed as PICO (population-intervention-comparison-outcome) and
addressed in clinical trials
➣ Provide training for reviewers of funding applications (including
patient and public reviewers) about the JLA PSP process, and support a
systematic approach (e.g. with criteria) for reviewers to judge whether a
research proposal genuinely reflects a prioritised question
For academic journals
➣ Designate and promote a specific publication genre (‘Research
Priority Setting’) for PSPs (and others) to publish their findings
➣ Encourage peer reviewers of such publications to be aware of the
steps set out in the JLA guidebook
➣ Tag such publications with standard key words such as ‘research
priority setting’ to make them easily retrievable
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